| Bioactivity | Trilostane (Win 24540) is a competitive and orally active 3-β-hydroxysteroiddehydrogenase (3β-HSD) inhibitor. Trilostane is a synthetic nonhormonal steroid. Trilostane can be used for the research of breast cancer and prostate cancer[1][2]. | ||||||||||||
| Invitro | Trilostane 剂量和时间依赖性地影响肾上腺皮质孕烯醇酮代谢[2]。Trilostane 选择性地抑制肾上腺中孕烯醇酮转化为孕酮[2]。 | ||||||||||||
| In Vivo | Trilostane (5.3-50 mg/kg；口服，每天 1 次，持续 3 个月) 控制狗体内垂体依赖性的高肾上腺皮质激素含量[1]。 Animal Model: | ||||||||||||
| Name | Trilostane | ||||||||||||
| CAS | 13647-35-3 | ||||||||||||
| Formula | C20H27NO3 | ||||||||||||
| Molar Mass | 329.43 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. JA Braddock, et al. Trilostane treatment in dogs with pituitary-dependent hyperadreno-corticism. Veterinary Journal. 10 March 2008. [2]. Ouschan C, et al. The influence of trilostane on steroid hormone metabolism in canine adrenal glands and corpora lutea-an in vitro study. Vet Res Commun. 2012 Mar;36(1):35-40. |